Слайд 18Литература:
1. Mauri L, Kereiakes DJ, Yeh RW, et al. Twelve or 30 months of
dual antiplatelet therapy after drug-eluting stents. The New England journal of medicine. 2014;371:2155–2166. [PMC free article] [PubMed]
2. Jernberg T, Hasvold P, Henriksson M, Hjelm H, Thuresson M, Janzon M. Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective. European heart journal. 2015 [epub ahead of print] [PubMed]
3. van Werkum JW, Heestermans AA, Zomer AC, et al. Predictors of coronary stent thrombosis: the Dutch Stent Thrombosis Registry. Journal of the American College of Cardiology. 2009;53:1399–1409.[PubMed]
4. Authors/Task Force m. Windecker S, Kolh P, et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI) European heart journal. 2014;35:2541–2619. [PubMed]
5. Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Journal of the American College of Cardiology. 2011;58:e44–e122. [PubMed]
6. Tanguay JF, Bell AD, Ackman ML, et al. Focused 2012 update of the Canadian Cardiovascular Society guidelines for the use of antiplatelet therapy. The Canadian journal of cardiology. 2013;29:1334–1345.[PubMed]
7. Bhatt DL, Fox KA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. The New England journal of medicine. 2006;354:1706–1717. [PubMed]
8. Mauri L, Kereiakes DJ, Normand SL, et al. Rationale and design of the dual antiplatelet therapy study, a prospective, multicenter, randomized, double-blind trial to assess the effectiveness and safety of 12 versus 30 months of dual antiplatelet therapy in subjects undergoing percutaneous coronary intervention with either drug-eluting stent or bare metal stent placement for the treatment of coronary artery lesions. American heart journal. 2010;160:1035–1041. 1041 e1. [PubMed]
9. Kereiakes DJ, Yeh RW, Massaro JM, et al. Antiplatelet therapy duration following bare metal or drug-eluting coronary stents: the Dual Antiplatelet Therapy Randomized Clinical Trial. Jama. 2015 (accepted for publication) [PMC free article] [PubMed]
10. Garratt KN, Weaver WD, Jenkins RG, et al. Prasugrel plus aspirin beyond 12 months is associated with improved outcomes after taxus liberte Paclitaxel-eluting coronary stent placement. Circulation. 2015;131:62–73. [PubMed]
11. Cutlip DE, Windecker S, Mehran R, et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007;115:2344–2351. [PubMed]
12. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. The GUSTO investigators. The New England journal of medicine. 1993;329:673–682.[PubMed]